Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy

Vito Lorusso, Marianna Giampaglia, Luciana Petrucelli, Valeria Saracino, Tania Perrone, Antonio Gnoni

Research output: Contribution to journalArticle

Abstract

Introduction The goal of pharmacological prophylaxis of chemotherapy-induced nausea and vomiting (CINV) should be the elimination of both nausea and vomiting symptoms during all planned chemotherapy cycles. The aim of this study was to assess the efficacy of a single dose of palonosetron and dexamethasone to prevent CINVand to guarantee an adequate food intake (FI) in patients receiving several cycles of multiple day-based chemotherapy (MD-CT). Methods Patients with advanced cancer but without a compromised nutritional status (bone mass index≥18.5) were treated with 0.25 mg palonosetron plus 20 mg dexamethasone before MD-CT. The MD-CT regimen was either epirubicin plus ifosfamide or paclitaxel plus cisplatin and ifosfamide. Nausea, vomiting, and FI were monitored in a 7-day diary. Complete response (CR: no vomiting and no rescue therapy) was the primary endpoint, while complete control (CC: CR and no more than mild nausea) and the evaluation of FI were secondary endpoints. The endpoints were evaluated during the overall timescale (0-168 h) of the chemotherapy regimen. Results Fifty patients were enrolled, 80% of whom achieved CR and 78% achieved CC. During the six chemotherapy cycles, CR and CC ranged from 76% to 88% and from 62% to 88%, respectively. Moreover, patients with CR had a significantly (p

Original languageEnglish
Pages (from-to)3241-3246
Number of pages6
JournalSupportive Care in Cancer
Volume20
Issue number12
DOIs
Publication statusPublished - Dec 2012

    Fingerprint

Keywords

  • Chemotherapy-induced nausea and vomiting (CINV)
  • Food intake
  • Multiple cycles
  • Multiple day chemotherapy
  • Palonosetron

ASJC Scopus subject areas

  • Oncology

Cite this